Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.32 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27471377 | 0.77 | MYC (0.51) | KDM4EGAAALDH1A1HPGDGRM4 | |
| SCHEMBL7769435 | 0.76 | ALDH1A1 (0.41) | KDM4ECA12CA1CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21800936 | 0.74 | GRM4 (0.39) | KDM4ECA12CA1CA9GAA | |
| SCHEMBL6887707 | 0.72 | CA12 (0.48) | CA12CA1CA9GAAALDH1A1 | |
| SCHEMBL317703 | 0.71 | KEAP1 (0.43) | KDM4ECA12CA1CA9GAA | |
| SCHEMBL31653832 | 0.71 | KEAP1 (0.43) | KDM4ECA12CA1CA9GAA | |
| SCHEMBL317626 | 0.71 | CA12 (0.42) | KDM4ECA12CA1CA9GAA | |
| SCHEMBL9596295 | 0.71 | CA12 (0.39) | KDM4ECA12CA1CA9GAA | |
| SCHEMBL1464604 | 0.70 | CA12 (0.41) | KDM4ECA12CA1CA9GAA | |
| SCHEMBL610788 | 0.70 | CA12 (0.41) | KDM4ECA12CA1CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2845866-B1 | Antibodies and immunoconjugates and uses therefor | GENENTECH INC (US) | 2017-05-03 | — | — | EP | claimed |
| EP-2447282-B1 | Anti-CD22 Antibodies, their Immunoconjugates and uses thereof | GENENTECH INC (US) | 2016-01-27 | — | — | EP | claimed |
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| EP-2176295-B1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2014-11-19 | — | — | EP | claimed |
| EP-2474557-B1 | Anti-CD79b antibodies and immunoconjugates and methods of use | GENENTECH INC (US) | 2014-08-20 | — | — | EP | claimed |
| EP-2032606-B1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH INC (US) | 2013-11-27 | — | — | EP | claimed |
| EP-2061814-B1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH INC (US) | 2012-06-06 | — | — | EP | claimed |
| US-7902328-B2 | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof | ABBOTT LABORATORIES (US) | 2011-03-08 | — | — | US | claimed |
| EP-0942996-B1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | DIATIDE INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1346731-B1 | Conjugates for treating inflammatory disorders and associated tissue damage | OSPREY PHARMACEUTICALS LTD (CA) | 2006-12-06 | — | — | EP | claimed |
| EP-0941738-B1 | Antigenic conjugates of conserved lipooligosaccharides of gram negative bacteria | WYETH CORP (US) | 2005-05-11 | — | — | EP | claimed |
| EP-0683822-B1 | PREPARATION OF PHOTOPROTEIN CONJUGATES AND METHODS OF USE THEREOF | SEALITE SCIENCES INC (US) | 2002-05-02 | — | — | EP | claimed |
| EP-0591369-B1 | CAPSID FORMING AND CYSTEIN MODIFIED CHIMAERIC MS2-COAT PROTEIN | BTG INT LTD (GB) | 2001-09-19 | — | — | EP | claimed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-5670381-A | TESTING DEVICE WITH DETECTABLE LABELS, DIFFUSIVE INDICATOR AND CAPTURE REAGENTS, REACTION ZONE AND BINDERS WITH OVERLAPPING | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0331068-B1 | IMMUNOASSAY AND -ROLYMERIC IGG DERIVATIVES TO COMPENSATE FOR INTERFERENCE FACTORS IN IMMUNOASSAYS | Roche Diagnostics GmbH (DE) | 1992-11-04 | — | — | EP | disclosed |
| EP-0331068-A1 | Immunoassay and -rolymeric IgG derivatives to compensate for interference factors in immunoassays | Roche Diagnostics GmbH (DE) | 1989-09-06 | — | — | EP | disclosed |
| EP-0282021-A2 | Specific antibody against heart muscle myosin light chains, its preparation and use in a reagent for the determination of heart muscle myosin light chains | Roche Diagnostics GmbH (DE) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | KDM4E 300/4885CA12 365/4885CA1 838/4885 |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | KDM4E 300/4885CA12 365/4885CA1 838/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | KDM4E 300/4885CA12 365/4885CA1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.